Web6 sep. 2024 · Iscalimab (CFZ533) Novartis/Xoma: Anti-CD40 MAb: Cirrus-1 in kidney transplant discontinued; see table below for other studies: ABBV-323 (ravagalimab) Abbvie: Anti-CD40 MAb: Possibly abandoned in ulcerative colitis; presumed abandoned in … Web24 okt. 2024 · Iscalimab is a fully human, CD40 pathway blocking, nondepleting monoclonal antibody being developed as an immunosuppressive agent. We describe a first-in …
Novartis to discontinue trial of CFZ533 in kidney transplant patients
Web3 jan. 2024 · Iscalimab overview. Iscalimab is under development for the treatment of type 1 diabetes mellitus, myasthenia gravis, primary Sjogren's syndrome, lupus nephritis and … Web3 sep. 2024 · An interim analysis of data from the CIRRUS-1 trial suggested that iscalimab (CFZ533) was less effective than tacrolimus at preventing rejection in kidney transplant … difference from the mean
Novartis scraps kidney transplant trial after control beats study …
Web3 sep. 2024 · Novartis has halted a clinical trial of CFZ533 (iscalimab) in kidney transplant patients after interim data showed it was not as good as tacrolimus-based treatment in … Web3 sep. 2024 · The study data apparently indicated that iscalimab was not as effective as tacrolimus at preventing organ rejection in kidney transplant patients when both were … Web9 jun. 2024 · Novartis halts iscalimab study in kidney transplant. 06-09-2024 Print. Swiss pharma giant Novartis has announced that, following an interim analysis of data from the … forman mechanical